Last week, nanotoxicology expert David W. Hobson suggested that industry must step up to gather and assess data on the safety of nanomaterials before government alone shapes a new regulatory model. This week he lays out some specific suggestions for companies to take proactive responsibility for determining how nanomaterials will be regulated.

Read about it in tomorrow's edition of MDD Perspectives, an op-ed e-zine that provides fresh commentary and opinions on issues that you can't find anywhere else. And best of all, it's free. If you don't already subscribe to this complimentary e-zine, go to medicaldevicedaily.com to sign up.